This year's ViVE conference featured a variety of news announcements — from company launches to new products to partnerships to acquisitions and more. In this list, MedCity News compiled short summaries for nine of the conference's most notable announcements.
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
In response to emailed questions, executives from Biofourmis, Force Therapeutics and Project Ronin shared products they're developing in remote patient monitoring as part of the broader hospital at home trend.
The Series D round of funding makes Biofourmis a unicorn valued at $1.3 billion. CEO and founder Kuldeep Singh Rajput said that the new capital will be used to expand his company’s remote-monitoring technologies and continue development of digital therapeutics, both as companions to traditional drugs and as monotherapies.
In our first in-person event in two years, the MedCity INVEST conference March 28-30 at the Ritz Carlton Hotel in Chicago, there will be many opportunities to connect with startups, investors and potential collaboration partners.
The application window is open for the startup contest Pitch Perfect at INVEST March 28-30 at the Ritz Carlton in Chicago. Here's a look at some of the participants in the contest and progressed they've made on their mission to improve healthcare.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Neuroglee recently raised $10 million in funding and struck a partnership with Mayo Clinic. It’s building a digital therapeutic and virtual programs for people with mild cognitive impairment.
Biofourmis, a Boston-based digital health startup, recently received breakthrough designation for its digital therapeutic to help ensure heart failure patients receive medications that are consistent with clinical evidence at the right dose.
Biofourmis, a Boston-based company that makes software-based therapeutic platforms, raised $100 million in a series C round led by SoftBank’s second Vision Fund. The company currently has developed a digital therapeutic for heart failure patients with Novartis, and plans to expand into other clinical areas.
The companies will test Biofourmis' sensor and artificial intelligence system in a clinical trial of more than 120 women with endometriosis.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Biofourmis, a Boston-based startup that uses analytics to predict problems in patients with heart failure, acquired Gaido Health from Takeda Pharmaceuticals. The startup said the deal would help it expand its work into oncology.
Biofourmis's CEO boldly declared the company will become a unicorn and this acquisition is expected to give the startup access to more raw data as it expands its analytics platforms and brings Biovotion's Everion wearable armband inhouse.
The company is moving its headquarters from Singapore to Boston alongside the capital raise.